A phase 1b dose-escalation/expansion study of BET inhibitor RO6870810 in patients with advanced multiple myeloma

by Karthik Ramasamy, Ajay Nooka, Hang Quach, Myo Htut, Rakesh Popat, Michaela Liedtke, Sascha A. Tuchman, Jacob Laubach, Cristina Gasparetto, Asher Chanan-Khan, Mark Hertzberg, Mark deMario, Eveline Nueesch, Evelyne Chesne, Izolda Franjkovic, Katharina Lechner, Martin Kornacker, Hearn Jay Cho
Published 2021-09-01

370 Pharmacodynamic assessment of a novel FAP-targeted 4–1BB agonist, administered as single agent and in combination with atezolizumab to patients with advanced solid tumors

by Josep Tabernero, Maurizio Ceppi, Victor Moreno, Michael Hettich, Miguel Sanmamed, Christina Claus, Tatiana Hernandez, Iben Spanggaard, Analia Azaro, Maria Martinez Garcia, Alejo Rodriguez-Vida, Florian Heil, Oliver Krieter, Oliver Grimm, Marta Canamero, Jose Duarte, Alexandra-Cristina Nica, Iakov Davydov, Chia-Huey Ooi, Christian Heichinger, Ernesto Guarin, Radoiane Helbaj, Tamara Tanos, Eveline Nueesch, Irene Moreno
Published 2020-11-01